Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high
Neurocrine Biosciences has appointed Eiry W. Roberts, M.D., as its new chief medical officer, succeeding Sanjay Keswani. The company reported strong second-quarter 2026 revenues of USD 959 million, a 39.50 percent increase year-over-year, and raised its 2026 INGREZZA net sales guidance. Despite these positive financial results, the stock remains 23.07 percent below its 52-week high, with UBS lowering its price target due to competitive and safety concerns.
Neurocrine Biosciences Shares Jump on Fresh Long-term CRENESSITY Data Catalyst
NULL
Neurocrine names Eiry W. Roberts CMO and Neurocrine Biosciences stock gains 1.74 percent
Neurocrine Biosciences has appointed Eiry W. Roberts as Chief Medical Officer, a role she previously held. This strategic move aims to bolster the company's late-stage programs, including INGREZZA and crinecerfont. The announcement follows strong Q2 2026 revenue of USD 959.0 million, a 39% increase year-over-year, and a 1.74% gain in stock value.
(NBIX) Movement as an Input in Quant Signal Sets
This article analyzes Neurocrine Biosciences Inc. (NASDAQ: NBIX) through quantitative research, highlighting positive near-term sentiment within a long-term strength context despite a mid-term weak bias. It identifies a significant 41.1:1 risk-reward setup, targeting an 11.9% gain against a 0.3% risk. The analysis also provides three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels.
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation
Neurocrine Biosciences (NBIX) is highlighted as an "Affordable Growth" stock, exhibiting strong growth, reasonable valuation, and solid profitability and financial health. The company shows exceptional earnings per share and revenue growth, with a forward P/E ratio that is attractive compared to industry peers, despite some recent margin declines. Its robust balance sheet, marked by zero debt and consistent positive earnings, underpins its financial stability.
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences (NBIX) will present research on Prader-Willi syndrome and VYKAT XR at the FPWR Annual Research Symposium & Family Conference from October 7-10 in Philadelphia. The presentations will include findings from two ongoing observational studies, PWS-VISTA and BRAVE-PWS, which aim to track VYKAT XR use, long-term safety, treatment outcomes, and gather caregiver-reported experiences. The company will also present integrated analyses on adverse events and long-term hyperphagia management.
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return
Neurocrine Biosciences announced the return of Eiry W. Roberts, M.D., as Chief Medical Officer, a role she previously held. Her return is seen as providing continuity, especially given her past guidance on INGREZZA expansions and the crinecerfont program that led to CRENESSITY's approval. This leadership change is expected to reinforce execution quality for late-stage clinical programs and the sustained adoption of existing products, aligning with analyst forecasts for significant revenue and earnings growth by 2029.
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return
Neurocrine Biosciences announced the return of Eiry W. Roberts, M.D., as Chief Medical Officer, a role she previously held. Her return is seen as a move for continuity, particularly given her past success with INGREZZA expansions and the CRENESSITY program. This leadership change is expected to reinforce the company's execution quality in late-stage clinical trials and product launches, influencing future revenue and earnings projections for its neurological and CNS pipeline.
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences will present new research at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference. The research focuses on advancing the understanding of Prader-Willi Syndrome (PWS) and expanding clinical and real-world evidence for VYKAT® XR, the only FDA-approved treatment for hyperphagia in PWS patients aged 4 and older. Key presentations will include findings from observational studies (PWS-VISTA and BRAVE-PWS) and integrated analyses of VYKAT XR's adverse events, underscoring the company's commitment to the PWS community.
Neurocrine Biosciences Welcomes Back Eiry Roberts as Chief Medical Officer
Neurocrine Biosciences has reappointed Eiry Roberts, MD, as Chief Medical Officer, a position she previously held from 2018 to 2025. During her prior tenure, Roberts played a key role in the development and FDA approval of Ingrezza and Crenessity. Her return is expected to provide continuity and advance the company's clinical development programs.
Neurocrine Biosciences selects Ruder Finn as communications AOR
Neurocrine Biosciences has appointed Ruder Finn as its communications agency of record following a competitive review process. Ruder Finn will focus on elevating awareness and storytelling for Neurocrine's pipeline in neuropsychiatry and endocrinology, leveraging its expertise in science communications, patient communities, and AI offerings. This win contributes to the continued growth of Ruder Finn's health practice.
Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return
Neurocrine Biosciences (NBIX) is seeing renewed attention following the return of its Chief Medical Officer, Eiry W. Roberts, M.D. The company's shares recently closed at US$140.44, with a common valuation narrative suggesting it is 34% undervalued, with a fair value of $213.13 per share. While cash flow models indicate undervaluation, the company's P/E ratio of 20.2x, compared to the industry average of 17.1x, suggests it is already trading at a premium.
UBS cuts Neurocrine Biosciences stock price target to $214 on competition
UBS has lowered its price target for Neurocrine Biosciences (NASDAQ:NBIX) to $214 from $231, while maintaining a Buy rating. This adjustment reflects concerns over increased competition and safety findings for one of its drugs, despite the stock trading at an attractive valuation and appearing on InvestingPro's Most Undervalued list. The firm believes the stock could act as a defensive play with limited downside, supported by a discounted cash flow framework and an oversold RSI.
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Neurocrine Biosciences, Inc. (NBIX) stock, including its current price, historical data, financial performance, and analyst ratings. The company specializes in developing pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders. Key financial metrics, product pipeline, and performance against the S&P 500 are also detailed.
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
Neurocrine Biosciences announced the reappointment of Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr. Roberts previously served in the role from 2018 to 2025 and has been a Strategic Advisor. She will lead the company's clinical development efforts, replacing Sanjay Keswani, M.D., who is departing.
Neurocrine names Eiry Roberts chief medical officer
Neurocrine Biosciences (NBIX) has appointed Eiry W. Roberts, M.D., as its new chief medical officer, effective September 28, 2026, succeeding Sanjay Keswani, M.D. Dr. Roberts' compensation package includes an annual base salary of $825,000, a 2026 annual cash incentive bonus target of 60% of base pay, and significant equity grants. The equity awards, comprising stock options, restricted stock units, and performance-vesting restricted stock units, will be granted after the company files its first Form 10-Q following the transition.
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
Neurocrine Biosciences has announced the re-appointment of Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr. Roberts previously served in the role from 2018 to 2025 and has been a Strategic Advisor to the company. She will lead the company's clinical development efforts, replacing Sanjay Keswani, M.D.
Neurocrine Biosciences names Eiry Roberts as chief medical officer By Investing.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has announced the return of Eiry W. Roberts, M.D., as its Chief Medical Officer, effective immediately. Dr. Roberts previously served in this role from 2018 to 2025 and has been a Strategic Advisor to the company. Her return is expected to provide strong continuity for the company's advancing late-stage programs and upcoming clinical milestones.
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer
Neurocrine Biosciences (NBIX) announced on Monday that Eiry Roberts will rejoin the company as its Chief Medical Officer. This news was reported by MT Newswires. The full article text is accessible to premium subscribers.
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts
This Yahoo Finance page is an error page for a stock forecast for Neurocrine Biosciences, Inc. (NBIX). It appears there was an issue retrieving the data, preventing the display of the intended content. The page also includes general market data for Canada and other global markets.
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts
This page from Yahoo Finance appears to be a placeholder or an error page for Neurocrine Biosciences, Inc. (NBIX) stock forecasts. It contains extensive navigation and footer elements typical of a financial news site but lacks specific content related to NBIX stock forecasts, instead showing an "Oops, something went wrong" message and an "Error in retrieving data." The page also displays real-time market data for various indices, commodities, and cryptocurrencies.
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
Neurocrine Biosciences (NBIX) has experienced strong revenue growth in 2026, primarily driven by its blockbuster drug Ingrezza, which saw sales increase by 17% in the first half of the year. The company raised its full-year guidance for Ingrezza sales, anticipating continued commercial momentum from its tardive dyskinesia and Huntington's disease chorea indications. However, potential pricing pressure from competitor Teva Pharmaceuticals (TEVA) and emerging alternative treatments could challenge Ingrezza's long-term sales trajectory.
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball
Zacks Equity Research highlights NVIDIA (NVDA), Neurocrine Biosciences (NBIX), and Ball Corp. (BALL) as top investment opportunities for the second half of 2026 due to their strong earnings growth. NVIDIA, with a 90.8% expected growth rate, and Neurocrine Biosciences, at 48.4%, are top-ranked by Zacks, alongside Ball Corp. with an 11.8% growth rate, all demonstrating impressive profitability. The article emphasizes the importance of earnings growth and accurate earnings estimates in guiding investment decisions and identifying stocks poised for significant market moves.
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating
RBC has reduced its price target for Neurocrine Biosciences (NBIX) to $187 from $198, while maintaining an "Outperform" rating on the stock. This adjustment comes despite the bank's continued positive outlook on the biopharmaceutical company. Neurocrine Biosciences is focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders.
Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock?
Neurocrine Biosciences' investment case is being strengthened by positive Phase 4 KINECT-PRO data for INGREZZA, showing clinically measured and patient-reported relief in tardive dyskinesia, and raised full-year guidance. While this reinforces INGREZZA's durability and supports the company's core thesis, potential pricing pressures from payers and Medicare negotiations remain a key short-term risk. The company aims to broaden its portfolio with new products like CRENESSITY and VYKAT XR to reduce reliance on INGREZZA and mitigate future risks.
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for Neurocrine Biosciences, Inc. (NBIX), including its current stock price, historical data, key statistics, company overview, recent news, and analyst ratings. The stock closed at $146.23 with a pre-market price of $147.94, and the company focuses on developing pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders.
Neurocrine CFO Matt Abernethy sells $363,284 in NBIX shares
Neurocrine Biosciences CFO Matt Abernethy sold 2,311 shares of NBIX common stock worth $363,284 on September 14, 2026, under a Rule 10b5-1 trading plan. This transaction followed his acquisition of 5,020 shares on September 11, 2026, which vested as performance restricted stock units, with some shares withheld for tax purposes. The company demonstrates strong revenue growth and is considered undervalued by InvestingPro analysis, despite a recent stock decline.
Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock
David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc., sold 826 shares of company stock for approximately $130,050 on September 14, 2026, as part of a Rule 10b5-1 trading plan. This transaction followed his acquisition of 3,587 shares from vested performance restricted stock units and occurred amid recent strong sales results for Neurocrine's drugs Ingrezza and Crenessity, leading to raised price targets from analysts despite ongoing safety concerns for Vykat.
Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock
David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold 826 shares for approximately $130,050 on September 14, 2026, as part of a Rule 10b5-1 trading plan. This sale followed his acquisition of 3,587 shares from vested restricted stock units and 98 shares from an employee stock purchase plan. Despite the stock's recent 3.3% decline, it remains up 15.5% over six months, and InvestingPro analysis suggests it is undervalued with a P/E of 22.05 and a PEG ratio of 0.21.
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) Grants 3,587 Shares to CSO Onyia Jude at No Cost
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) awarded its Chief Scientific Officer, Onyia Jude, 3,587 shares at no cost on September 11, 2026. This transaction initially increased Jude's holdings to 24,583 shares. However, a subsequent forfeiture of 1,936 shares at $156.22 reduced his reported holdings to 22,647 shares.
Neurocrine Biosciences CMO Sanjay Keswani Reports Vesting of 3,914 PRSUs with Tax Withholding
Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), reported the vesting of 3,914 performance restricted stock units (PRSUs) on September 11, 2026. Following the vesting, 2,112 shares were withheld by Neurocrine Biosciences for tax obligations at $156.22 per share, with no open-market sale involved. Keswani's direct beneficial ownership now stands at 3,281 shares of common stock.
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08
Neurocrine Biosciences, Inc. presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, at 08:35 AM EDT. The transcript highlights an introduction by Josh Schimmer from Cantor's biotech equity research team, with the full content available to subscribers. The article also lists recent news and financial updates concerning Neurocrine Biosciences, including their participation in other conferences, drug development milestones, and analyst rating adjustments.
Neurocrine Biosciences stock rating reaffirmed by RBC Capital
RBC Capital reiterated an Outperform rating for Neurocrine Biosciences (NASDAQ:NBIX) with a $198.00 price target, highlighting the company's undervaluation given its $16 billion market capitalization relative to expected sales of Ingrezza and Crenessity. The firm anticipates strong second-half 2026 results from these drugs and potential upside from Vykat performance, despite acknowledging higher risks and distant timelines for late-stage pipeline programs. The report also notes recent strong Q2 sales for Ingrezza and Crenessity, leading to raised price targets from other firms, alongside concerns about Vykat's safety profile and ongoing pipeline progress.
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Nxera Pharma's partner Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567 for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment as a result. NBI-1117567 is an oral, muscarinic M1 preferring (M1/M4) selective agonist, part of a broader collaboration between the two companies to develop muscarinic receptor agonists for neuropsychiatric disorders.
Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run
Neurocrine Biosciences (NBIX) stock has seen a 59% return over five years but still appears undervalued based on its current P/E ratio compared to its tailored fair multiple and industry peers. Despite positive attention from new study results for INGREZZA, the market is not yet fully pricing in a premium, suggesting potential for further upside if earnings and cash flow from key drugs continue to develop favorably.
Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run
Neurocrine Biosciences (NBIX) stock has seen a 59% return over the past five years but remains undervalued according to Simply Wall St's metrics. Its current P/E ratio of 22.0x is below the industry peer average and a tailored fair multiple, suggesting the market isn't fully pricing in its potential. The company's future stock performance hinges on its earnings and cash flow development from key drugs like INGREZZA, alongside managing clinical, regulatory, and competitive risks.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine Biosciences (NBIX) is expected to report significant year-over-year growth in earnings and revenues for the quarter ended June 2026, with analysts forecasting $2.24 EPS and $894.32 million in revenue. The company has a Zacks Rank #1 (Strong Buy) and a positive Earnings ESP of +3.77%, suggesting a high probability of beating consensus EPS estimates. Investors will be watching the July 30 release closely, as NBIX has historically beaten EPS estimates in three of the last four quarters.
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
Neurocrine Biosciences (NBIX) reported Q1 earnings of $1.94 per share, surpassing the Zacks Consensus Estimate of $1.68 and significantly up from $0.08 a year ago. The company also exceeded revenue expectations, posting $814.5 million against an estimate of $741.8 million. Despite underperforming the S&P 500 year-to-date, Neurocrine currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance.
Here's Why Neurocrine Biosciences (NASDAQ:NBIX) Has Caught The Eye Of Investors
Neurocrine Biosciences (NASDAQ:NBIX) has attracted investor attention due to its strong performance, with its stock price appreciating 59% over the past five years and its earnings per share growing by 21% annually. The company's high return on equity and significant profit retention suggest effective capital reinvestment and potential for continued growth. This combination of factors indicates why investors are taking a closer look at NBIX.
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine Biosciences (NBIX) exceeded Q2 expectations with strong revenue and adjusted EPS, largely driven by its flagship therapy Ingrezza, for which the company also raised its 2026 sales outlook. While newer products like Crenessity and Vykat XR are broadening the portfolio, Ingrezza remains the primary revenue driver, prompting increased research and commercial spending. The company's future growth hinges on maintaining prescription momentum and successful product launches, balanced against rising operational costs.
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine Biosciences (NBIX) reported better-than-expected Q2 results, with revenues and adjusted EPS surpassing estimates, and raised its 2026 Ingrezza sales guidance. The company's growth is driven by Ingrezza, Crenessity, and the new Vykat XR, despite increased research and commercial spending. While the strong performance supports the revenue story, increased operating investments and execution risks, including Vykat XR retention and Ingrezza pricing, balance the outlook.
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) is highlighted as potentially undervalued by 28% after new INGREZZA data showed sustained improvements in tardive dyskinesia symptoms. Despite recent share price choppiness, the company's broad CNS pipeline and internal innovation support a higher intrinsic value of approximately $213 per share according to analyst narratives. However, its P/E ratio is higher than the US biotech industry, indicating mixed signals for investors.
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth potential. However, the valuation hinges on successful execution for INGREZZA and CRENESSITY, with risks from pricing pressure and higher SG&A.
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) has released new KINECT-PRO Phase 4 results for INGREZZA, showing sustained improvements in tardive dyskinesia symptoms and patient quality of life. Despite recent share price fluctuations, the company is seen as significantly undervalued by analysts, trading at a 27.5% discount to a fair value estimate of $213 per share. This valuation is supported by a robust CNS pipeline and ongoing innovation, though execution risks for INGREZZA and CRENESSITY, along with pricing pressures, remain potential challenges.
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
Neurocrine Biosciences (NBIX) stock has declined by 12% over the past month, despite strong Q2 2026 earnings, primarily due to safety concerns surrounding its newly acquired drug, Vykat XR. While Ingrezza remains a key revenue driver with strong growth, and Crenessity is rapidly expanding, the competitive landscape and pipeline execution risks suggest a "wait-and-watch" approach for investors until there's clearer visibility on Vykat XR's safety and commercial trajectory.
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V.
ABN AMRO Bank N.V. has purchased 14,787 shares of Neurocrine Biosciences (NASDAQ:NBIX), valued at approximately $2.51 million, during the second quarter. Other institutional investors have also adjusted their holdings in the company, with 92.59% of the stock owned by hedge funds and institutions. The stock holds a "Moderate Buy" consensus rating from analysts with an average price target of $200.86, despite recent insider sales totaling nearly $59.5 million.
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership?
Neurocrine Biosciences recently released positive Phase 4 KINECT-PRO results for INGREZZA, showing improved patient-reported quality of life and reduced tardive dyskinesia severity. While these findings strengthen INGREZZA's clinical profile, the company's investment narrative still hinges on volume growth amid payer scrutiny and its efforts to diversify its portfolio beyond movement disorders. Investors should consider the potential impact of pricing pressure on INGREZZA's future profitability.
S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX
S&CO Inc. has acquired a new stake in Neurocrine Biosciences, purchasing 7,000 shares valued at approximately $1.18 million during the second quarter. Institutional investors collectively own 92.59% of NBIX, and analysts maintain a "Moderate Buy" rating with an average price target of $200.86. Despite significant insider selling over the past 90 days, the company's stock has seen a 1.3% increase.
Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX
Focus Partners Advisor Solutions LLC has invested $1.93 million in Neurocrine Biosciences, Inc. by purchasing 11,434 shares in the second quarter. Institutional investors hold 92.59% of NBIX shares, while company insiders have sold a significant amount of stock recently. Analysts maintain a "Moderate Buy" rating with an average price target of $200.86, against the stock's recent opening price of $152.72.
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership?
Neurocrine Biosciences' INGREZZA showed positive Phase 4 results, improving patient-reported quality of life and tardive dyskinesia severity. The company aims to leverage this patient-centric data to solidify INGREZZA's leadership in neurology, while also working to diversify its portfolio beyond movement disorders and manage potential pricing pressures. Analysts project significant revenue and earnings growth for Neurocrine by 2029, suggesting a potential upside to its current stock price.
